A 5-year-old boy from Tamil Nadu presents with blue sclerae, short stature, and recurrent bone fractures after minor trauma. His parents are consanguineous. Serum alkaline phosphatase is elevated, and X-rays show generalized osteopenia with thin cortices. A skin biopsy reveals reduced type I collagen content. Genetic testing confirms a heterozygous mutation in COL1A1. What is the primary biochemical consequence of this mutation in osteogenesis imperfecta?

Explanation

## Clinical Diagnosis: Osteogenesis Imperfecta (OI), Type I ### Pathophysiology of COL1A1 Mutations **Key Point:** Type I collagen is the most abundant protein in bone matrix and provides tensile strength. COL1A1 and COL1A2 mutations account for ~90% of osteogenesis imperfecta cases. These mutations cause either: 1. **Quantitative defect** — reduced collagen production (haploinsufficiency) 2. **Qualitative defect** — abnormal collagen structure with impaired triple helix stability **High-Yield:** In OI, the defect is in **collagen synthesis or structure**, not in post-translational modification enzymes. The patient's skin biopsy showing **reduced type I collagen content** confirms a quantitative defect (haploinsufficiency). ### Molecular Basis of OI Type I **OI Type I** (mild, autosomal dominant): - Heterozygous mutations in COL1A1 or COL1A2 - **Haploinsufficiency** — one mutant allele produces ~50% normal collagen - Reduced collagen quantity → weakened bone matrix - Blue sclerae (thin sclera allows choroid pigment to show through) - Hearing loss (collagen defect in ossicles) - Dental problems (dentin defects) **OI Type II** (perinatal lethal): - Homozygous or compound heterozygous mutations - Severe collagen deficiency → incompatible with life **OI Type III** (severe, progressive): - Mutations producing structurally abnormal collagen - Progressive deformity, severe osteoporosis ### Collagen Triple Helix Assembly ```mermaid flowchart TD A[COL1A1/COL1A2 genes]:::outcome --> B[Procollagen synthesis]:::action B --> C[Post-translational modifications:<br/>Prolyl/lysyl hydroxylation<br/>Glycosylation]:::action C --> D[Triple helix formation<br/>Gly-X-Y repeat critical]:::action D --> E[Procollagen secretion]:::action E --> F[Cleavage of propeptides]:::action F --> G[Mature collagen molecules]:::outcome G --> H[Cross-linking via lysyl oxidase]:::action H --> I[Stabilized collagen fibrils]:::outcome J[COL1A1 mutation]:::urgent --> K{Type of mutation?}:::decision K -->|Haploinsufficiency| L[Reduced collagen quantity]:::outcome K -->|Missense/structural| M[Abnormal triple helix]:::outcome L --> N[OI Type I: Mild]:::outcome M --> O[OI Type II/III: Severe]:::outcome ``` ### Why This Patient Has OI Type I - **Heterozygous COL1A1 mutation** → one functional allele produces ~50% normal collagen - **Blue sclerae** → thin sclera due to reduced collagen - **Osteopenia with thin cortices** → weakened bone matrix - **Elevated ALP** → increased bone turnover (compensatory) - **Recurrent fractures** → mechanically weak bones **Clinical Pearl:** The **blue sclerae are pathognomonic** for OI and reflect the thinness of the sclera allowing the choroid to show through. This distinguishes OI from other causes of osteoporosis. ### Differential Diagnosis: Other Collagen Defects | Condition | Gene/Defect | Primary Problem | Clinical Features | |-----------|-------------|-----------------|------------------| | **OI Type I** | COL1A1/COL1A2 (quantitative) | Reduced type I collagen | Blue sclerae, mild fractures, hearing loss | | **OI Type II** | COL1A1/COL1A2 (severe) | Severe collagen deficiency | Perinatal lethal, severe deformity | | **Ehlers-Danlos, Classical** | COL5A1/COL3A1 | Abnormal collagen structure | Skin hyperextensibility, joint hypermobility | | **Scurvy** | Vitamin C deficiency | Impaired hydroxylation | Bleeding, poor wound healing, bone pain | | **Menkes disease** | ATP7A (copper transport) | Lysyl oxidase deficiency | Kinky hair, neurodegeneration, vascular rupture | ## Why the Correct Answer is Correct COL1A1 mutations in OI cause either reduced collagen synthesis (haploinsufficiency) or structurally abnormal collagen with impaired triple helix stability. This patient's reduced collagen content on biopsy confirms the quantitative defect. The defect is in collagen synthesis/structure, not in post-translational modification enzymes.